LivaNova’s Strong Growth Potential Driven by Product Innovation and Market Expansion

Jefferies analyst Matthew Taylor maintained a Buy rating on LivaNova (LIVN – Research Report) on June 6 and set a price target of $79.00.

Matthew Taylor has given his Buy rating due to a combination of factors that highlight LivaNova’s strong growth potential. The company is experiencing a robust product cycle, particularly with the Essenz upgrade, which is expected to significantly boost revenue through an increase in average selling prices as the replacement cycle progresses. Additionally, LivaNova’s expansion in the oxygenator market, with a growing market share and increased production capacity, underscores its competitive edge.
Moreover, LivaNova’s advancements in its core Vagus Nerve Stimulation (VNS) therapy for epilepsy, demonstrated by impressive long-term data, reinforce its position in addressing drug-resistant epilepsy. The company’s strategic focus on internal execution for the commercialization of its Obstructive Sleep Apnea (OSA) solutions and the promising data from its Depression Treatment Device (DTD) pipeline further contribute to the positive outlook. These developments, along with potential market opportunities in treatment-resistant depression, underpin the Buy rating as they collectively indicate a strong trajectory for growth and market penetration.

In another report released on May 22, Piper Sandler also maintained a Buy rating on the stock with a $75.00 price target.

LIVN’s price has also changed slightly for the past six months – from $49.710 to $45.950, which is a -7.56% drop .